Bargains are getting harder and harder to find in the med-tech sector these days, and with Medtronic (NYSE:MDT) sporting a double-digit EV/EBITDA ratio
and a 35% gain in the share price over the last year, it doesn't
necessarily jump out as a bargain. Nevertheless, with signs of
stabilization evident in CRM and spine and some high profile products
coming out in a couple of years, Medtronic is still worth considering
even at this 52-week high.
Please continue here:
http://www.investopedia.com/stock-analysis/052213/medtronic-still-reporting-weak-growth-relatively-rare-bargain-mdt-bsx-stj-jnj.aspx
No comments:
Post a Comment